JBIO — Jade Biosciences, Inc.

JBIO

SHORT CANDIDATEMeanRev

Composite

34.80

Technical

18.20

Fundamental

40.40

Rank

—

Price

15.87

Hurst

0.24

As of

Nov 13, 2026

Daily

Jade Biosciences, Inc.

HealthcareBiotechnology

Jade Biosciences is a biotechnology firm focused on creating treatments for autoimmune and inflammatory disorders. The company's lead candidate, JADE101, is a monoclonal antibody targeting the APRIL protein and is currently undergoing phase 1 testing, while two additional programs, JADE201 and JADE-003, remain in earlier preclinical phases. The firm maintains a partnership with Paragon Therapeutics and is headquartered in Waltham, Massachusetts.

Market cap

$1.0B

P/E (trailing)

—

P/E (forward)

-6.06

PEG ratio

—

Dividend yield

0.00%

Beta

—

52w range

10.98 – 28.00

Return on equity

—

Profit margin

0.00%

Revenue growth

—

Earnings growth

—

Price history

1Y: 16.14 (+50.8%) · range 10.70–26.85

Cycle position

37/ 100 cycle scoreAPPROACHING ENTRY

ENTRYAPPROACHMID-BULLNEAR-TOPEXIT

entry readiness 51 · MODERATE · exit proximity 0

Conviction

41/ 100 · maturity 14%

VScore.0919

Buildup.3035

EMA entry setup.3851

Fundamentals.2340

Volume profile

POC

14.67

Price vs POC

+8.2%

Overhead supply

70%

Runway

+6.2%

Value area 13.09–20.87 · 70% of 120d volume overhead · heavy supply

Get an AI analyst's read on this ticker.Open the AI analyst

Contributing sources

Source	Score	Last seen
earnings-surprise	0.967	Nov 13, 2026

Peer cluster

NEUTRAL

Forward returns

Not yet labeled — the study prices these as positions mature.